

# CITATION REPORT

List of articles citing

Therapeutic drug monitoring of antifungals:  
pharmacokinetic and pharmacodynamic considerations

DOI: 10.1097/ftd.ob013e318167doe0

Therapeutic Drug Monitoring, 2008, 30, 167-72.

**Source:** <https://exaly.com/paper-pdf/45019921/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
132	Therapeutic Drug Monitoring (TDM) of Antimicrobial Agents. <b>2008</b> , 40, 133		3
131	Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections. <b>2009</b> , 62, 469-82		8
130	Comparative efficacies of Zataria multiflora essential oil and itraconazole against disseminated Candida albicans infection in BALB/c mice. <b>2009</b> , 40, 439-45		24
129	Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. <b>2009</b> , 53, 1793-6		58
128	What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice?. <b>2009</b> , 53, 3608-9; author reply 609-10		6
127	A routine method for the quantification of the novel antimycotic drug posaconazole in plasma using liquid chromatography-tandem mass spectrometry. <b>2009</b> , 47, 579-84		15
126	Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis. <b>2009</b> , 43, 978-84		12
125	Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts. <b>2009</b> , 29, 1306-25		16
124	Bioanalytical methods for the determination of itraconazole and hydroxyitraconazole: overview from clinical pharmacology, pharmacokinetic, pharmacodynamic and metabolism perspectives. <b>2009</b> , 23, 677-91		5
123	Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient. <b>2009</b> , 29, 481-486		27
122	Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update. <i>Expert Review of Anti-Infective Therapy</i> , <b>2009</b> , 7, 165-81	5.5	14
121	Pharmacological properties of antifungal drugs with a focus on anidulafungin. <b>2009</b> , 69 Suppl 1, 79-90		14
120	International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. <b>2009</b> , 53, 303-5		51
119	Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography. <b>2009</b> , 53, 3140-2		26
118	Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 396-9	3.2	21
117	A rapid and sensitive LC-MS/MS method for determination of fluconazole in human plasma and its application in infants with Candida infections. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 703-9	3.2	25
116	Validated liquid chromatography-tandem mass spectroscopy method for the simultaneous quantification of four antimycotic agents in human serum. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 453-7	3.2	18

115	Antifungal Dosing in Critically Ill Patients. <b>2010</b> , 4, 78-86		3
114	The role of second-generation antifungal triazoles for treatment of the endemic mycoses. <b>2010</b> , 12, 471-8		6
113	Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. <b>2010</b> , 878, 39-44		77
112	Intracellular concentrations of posaconazole in different compartments of peripheral blood. <b>2010</b> , 54, 2928-31		37
111	Impact of glucuronide interferences on therapeutic drug monitoring of posaconazole by tandem mass spectrometry. <b>2010</b> , 48, 1723-31		16
110	Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of four triazole antifungal agents in human plasma. <b>2010</b> , 48, 1515-22		30
109	Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients. <i>Medical Mycology</i> , <b>2010</b> , 48 Suppl 1, S52-9	3.9	32
108	Voriconazole pharmacokinetics and pharmacodynamics in children. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 50, 27-36	11.6	177
107	Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry. <b>2010</b> , 54, 1815-9		68
106	Melanized fungi in human disease. <b>2010</b> , 23, 884-928		389
105	Antifungal treatment of small animal veterinary patients. <b>2010</b> , 40, 1171-88		36
104	Amphotericin B use in children: conventional and lipid-based formulations. <i>Expert Review of Anti-Infective Therapy</i> , <b>2011</b> , 9, 357-67	5.5	4
103	Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 86-93	3.2	54
102	[Level of evidence for therapeutic drug monitoring of voriconazole]. <b>2011</b> , 66, 109-14		7
101	Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 133-46	3.2	51
100	Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients. <i>Mycoses</i> , <b>2011</b> , 54, 230-3	5.2	5
99	Optimising absorption of posaconazole. <i>Mycoses</i> , <b>2011</b> , 54, e775-9	5.2	14
98	Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. <b>2011</b> , 67, 253-60		47

97	Antifungal Dosing in Dialysis and Continuous Renal Replacement Therapy. <b>2011</b> , 5, 75-82		2
96	Strategies to manage antifungal drug resistance. <b>2011</b> , 12, 241-56		6
95	Measurement of posaconazole, itraconazole, and hydroxyitraconazole in plasma/serum by high-performance liquid chromatography with fluorescence detection. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 735-41	3.2	11
94	Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 53, 1060-6	11.6	72
93	Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. <b>2011</b> , 55, 5780-9		36
92	Antifungal Pharmacokinetics and Pharmacodynamics. <b>2011</b> , 121-134		3
91	Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. <b>2011</b> , 55, 4782-8		168
90	Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. <b>2011</b> , 55, 5770-9		56
89	Therapeutic drug monitoring of antifungal agents <sup>1</sup> ). <b>2012</b> , 36, 1-10		
88	Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections. <b>2012</b> , 19, 51-63		7
87	Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. <b>2012</b> , 56, 2371-7		100
86	Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. <b>2012</b> , 67, 700-6		64
85	In vitro acquisition of secondary azole resistance in <i>Aspergillus fumigatus</i> isolates after prolonged exposure to itraconazole: presence of heteroresistant populations. <b>2012</b> , 56, 174-8		34
84	Pharmacokinetics of antifungal agents in neonates and young infants. <b>2012</b> , 19, 4621-32		5
83	Evaluation of the effect of obesity on voriconazole serum concentrations. <b>2012</b> , 67, 2957-62		33
82	Therapeutisches Drug Monitoring von Antimykotika/Therapeutic drug monitoring of antifungal agents. <b>2012</b> , 36,		
81	An on-line solid phase extraction procedure for the routine quantification of caspofungin by liquid chromatography-tandem mass spectrometry. <b>2011</b> , 50, 521-4		3
80	Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients. <i>Medical Mycology</i> , <b>2012</b> , 50, 439-45	3.9	23

79	Voriconazole-associated severe hyponatremia. <i>Medical Mycology</i> , <b>2012</b> , 50, 103-5	3.9	13
78	Antifungal property of dihydrodehydrodiconiferyl alcohol 9SO-beta-D-glucoside and its pore-forming action in plasma membrane of <i>Candida albicans</i> . <b>2012</b> , 1818, 1648-55		27
77	Rapid HPLC-MS/MS method for simultaneous quantitation of four routinely administered triazole antifungals in human plasma. <b>2012</b> , 413, 240-5		38
76	Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. <b>2012</b> , 39, 1-10		37
75	Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. <b>2012</b> , 39, 510-3		60
74	Optimal Sampling Times for Therapeutic Drug Monitoring. <b>2012</b> , 01,		
73	Therapeutic drug monitoring of antimicrobials. <b>2012</b> , 73, 27-36		197
72	Rapid and sensitive determination of posaconazole in patient plasma by capillary electrophoresis with field-amplified sample stacking. <b>2012</b> , 1226, 48-54		24
71	Therapeutic drug monitoring in voriconazole-associated hyponatremia. <b>2013</b> , 2, 134-6		2
70	Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. <b>2013</b> , 60, 82-7		35
69	A simple high-performance liquid chromatography method for simultaneous determination of three triazole antifungals in human plasma. <b>2013</b> , 57, 484-9		23
68	Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine <i>Aspergillus fumigatus</i> infection model. <b>2013</b> , 57, 1404-8		13
67	Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype. <b>2013</b> , 33, e19-22		18
66	Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. <b>2013</b> , 57, 6081-4		21
65	Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children. <b>2013</b> , 35, e219-23		36
64	Significance and biological importance of pyrimidine in the microbial world. <b>2014</b> , 2014, 202784		75
63	Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapy. <b>2014</b> , 25, 271-6		10
62	Synthesis and Antimicrobial Studies of Pyrimidine Pyrazole Heterocycles. <b>2014</b> , 2014, 1-12		9

61	Simultaneous determination of seven azole antifungal drugs in serum by ultra-high pressure liquid chromatography and diode array detection. <b>2014</b> , 69, 53-61	4
60	Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <b>2014</b> , 93, 13-32	94
59	[Pharmacology of the antifungals used in the treatment of aspergillosis]. <b>2014</b> , 31, 255-61	3
58	1,1?-Sulfinyldipyridinium bis (hydrogen sulfate) ionic liquid: synthesis and application in the temperature-influenced synthesis of novel pyranopyrimidinediones and pyranopyrimidinetrienes. <b>2014</b> , 4, 50449-50455	5
57	A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid. <b>2014</b> , 58, 424-31	49
56	Drugs Active against Fungi, Pneumocystis, and Microsporidia. <b>2015</b> , 479-494.e4	7
55	Successful empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic stem cell transplantation. <b>2015</b> , 35, 437-46	8
54	Training should be the first step toward an antifungal stewardship program. <b>2015</b> , 33, 221-7	15
53	Epidemiology of invasive fungal infections in lung transplant recipients on long-term azole antifungal prophylaxis. <b>2015</b> , 29, 311-8	34
52	Evaluation of sulfobutylether- $\beta$ -cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. <b>2015</b> , 19, 32	61
51	Impact of inflammation and concomitant glucocorticoid administration on plasma concentration of triazole antifungals in immunocompromised patients. <b>2015</b> , 441, 127-32	25
50	Antifungal therapeutic drug monitoring: when, how, and why. <b>2015</b> , 33, 295-7	3
49	Antifungal Drug Therapeutic Monitoring: What are the Issues?. <b>2015</b> , 2, 55-66	9
48	How much European prescribing physicians know about invasive fungal infections management?. <b>2015</b> , 15, 80	24
47	Blood and Marrow Transplant Handbook. <b>2015</b> ,	5
46	[Strategies for antifungal treatment failure in intensive care units]. <b>2015</b> , 64, 643-58	1
45	Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections. <b>2015</b> , 36, 767-85	31
44	Antifungal pharmacokinetics and pharmacodynamics. <b>2014</b> , 5, a019653	58

43	Antifungal Therapy. <b>2016</b> ,		3
42	Hepatic Failure in a Patient Receiving Itraconazole for Pulmonary Histoplasmosis-Case Report and Literature Review. <b>2016</b> , 23, e1215-21		4
41	Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels. <b>2016</b> , 60, 5595-9		18
40	Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. <b>2016</b> , 47, 124-31		60
39	Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications. <b>2016</b> , 30, 51-83		182
38	Antifungal Dosing Strategies for Critically Ill Patients. <b>2017</b> , 11, 5-15		2
37	Ultra-fast quantitation of voriconazole in human plasma by coated blade spray mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2017</b> , 144, 106-111	3-5	31
36	Voriconazole-induced hyponatraemia associated with homozygous CYP2C19*2 genotype. <b>2017</b> , 29, 325-326		1
35	Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use. <b>2017</b> , 29, 131-143		17
34	Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2017</b> , 13, 1135-1146	5-5	22
33	Notable Drug-Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19. <b>2017</b> , 57, 1491-1499		6
32	Dosing and therapeutic drug monitoring of voriconazole in bottlenose dolphins ( <i>Tursiops truncatus</i> ). <i>Medical Mycology</i> , <b>2017</b> , 55, 155-163	3-9	5
31	Optimizing Single-Drug Antibacterial and Antifungal Therapy. <b>2017</b> , 157-179		1
30	Pharmacokinetic-Pharmacodynamic Basis of Optimal Antibiotic Therapy. <b>2018</b> , 1478-1498.e6		1
29	Chiloscyphenol A derived from Chinese liverworts exerts fungicidal action by eliciting both mitochondrial dysfunction and plasma membrane destruction. <i>Scientific Reports</i> , <b>2018</b> , 8, 326	4-9	9
28	Case of femoral pseudarthrosis due to <i>Scedosporium apiospermum</i> in an immunocompetent patient with successful conservative treatment and review of literature. <i>Mycoses</i> , <b>2018</b> , 61, 400-409	5-2	1
27	Antibiotic Dosing in Pediatric Critically Ill Patients. <b>2018</b> , 239-263		2
26	Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill. <b>2018</b> ,		2

25	Crystal structure, spectroscopic (FT-IR, 1 H and 13 C NMR) characterization and density functional theory calculations on Ethyl 2-(dichloromethyl)-4-methyl-1-phenyl-6-thioxo-1,6-dihydropyrimidine-5-carboxylate. <i>Journal of Molecular Structure</i> , <b>2018</b> , 1171, 762-770	3.4	6
24	Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2019</b> , 15, 881-895	5.5	35
23	Isotope dilution LC-orbitrap-HRMS with automated sample preparation for the simultaneous quantification of 11 antimycotics in human serum. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2019</b> , 166, 398-405	3.5	7
22	Vinyl-functionalized mesoporous carbon for dispersive micro-solid phase extraction of azole antifungal agents from aqueous matrices. <i>Separation Science and Technology</i> , <b>2020</b> , 55, 3102-3112	2.5	1
21	Antifungal use in the surgical ICU patient. <i>Current Opinion in Anaesthesiology</i> , <b>2020</b> , 33, 131-138	2.9	0
20	Improvement of the pharmacokinetic/pharmacodynamic relationship in the treatment of invasive aspergillosis with voriconazole. Reduced drug toxicity through novel rapid release formulations. <i>Colloids and Surfaces B: Biointerfaces</i> , <b>2020</b> , 193, 111119	6	2
19	Evaluation of targeted versus universal prophylaxis for the prevention of invasive fungal infections following lung transplantation. <i>Transplant Infectious Disease</i> , <b>2021</b> , 23, e13448	2.7	2
18	Azoles. <b>2011</b> , 61-93		1
17	Infectious Complications. <b>2010</b> , 143-165		2
16	Current Controversies in the Treatment of Fungal Infections. <b>2011</b> , 301-316		1
15	Antifungal Therapeutic Drug Monitoring for Invasive Aspergillosis. <b>2009</b> , 217-228		1
14	Systemic Antifungal Agents. <b>2010</b> , 549-563		5
13	Pharmacokinetic/Pharmacodynamic Basis of Optimal Antibiotic Therapy. <b>2012</b> , 1433-1452.e10		2
12	Posaconazole in immunocompromised pediatric patients. <i>Expert Review of Anti-Infective Therapy</i> , <b>2018</b> , 16, 543-553	5.5	15
11	Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use. 343-371		3
10	Therapeutic Drug Monitoring of Voriconazole: Comparison of Bioassay with High-Performance Liquid Chromatography. <i>Jundishapur Journal of Microbiology</i> , <b>2017</b> , In press,	1.2	2
9	Polyenes for Prevention and Treatment of Invasive Fungal Infections. <b>2009</b> , 163-183		
8	4. Is Expansion of Therapeutic Drug Monitoring for Anti-Infective Agents Necessary?. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 43, 229-234		0



- 7 Infectious Complications. **2015**, 201-222
- 6 Nanostructure Drug Delivery System: An Inimitable Approach for Candidiasis Therapy. **2020**, 325-357
- 5 Electromembrane Extraction of Posaconazole for Matrix-Assisted Laser Desorption/Ionization Mass Spectrometric Detection. *Membranes*, **2022**, 12, 620 3.8 ○
- 4 Controversies in the Management of Central Nervous System Coccidioidomycosis. *Clinical Infectious Diseases*, 11.6 ○
- 3 Reducing Toxicity in Critically Ill Patients by Using Therapeutic Drug Monitoring. **2022**, 143-160 ○
- 2 Pharmacokinetic and Pharmacodynamic Basis of Optimal Antimicrobial Therapy. **2023**, 1516-1537.e7 ○
- 1 Management of Invasive Infections in Diabetes Mellitus: A Comprehensive Review. **2023**, 3, 40-71 ○